Firazyr

Firazyr is a brand name of icatibant, approved by the FDA in the following formulation(s):

FIRAZYR (icatibant acetate - injectable; subcutaneous)

• 
  Manufacturer: SHIRE ORPHAN THERAP
  
  Approval date: August 25, 2011
  
  Strength(s): EQ 30MG BASE/3ML (EQ 10MG BASE/ML) ^[RLD]

Has a generic version of Firazyr been approved?

No. There is currently no therapeutically equivalent version of Firazyr available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Firazyr. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Peptides having bradykinin antagonist action
  Patent 5,648,333
  Issued: July 15, 1997
  Inventor(s): Henke; Stephan & Anagnostopulos; Hiristo & Breipohl; Gerhard & Knolle; Jochen & Stechl; Jens & Scholkens; Bernward & Fehlhaber; Hans-Wolfram & Gerhards; Hermann & Hock; Franz
  Assignee(s): Hoechst Aktiengesellschaft
  Peptides of the formula I EQU A-B-C-E-F-K-P-G-M-F'-I (I), wherein the terms A, B, C, E, F, K, P, G, M, F', and I are defined in the specification, have bradykinin antagonist action. Their therapeutic utility includes all pathological states which are mediated, caused or supported by bradykinin and bradykinin-related peptides.
  
  Patent expiration dates:
  
  
  • July 15, 2014
    
    ✓ 
    Patent use: TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 25, 2016 - NEW CHEMICAL ENTITY
  
  
  • August 25, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Firazyr Consumer Information (Drugs.com)
• Firazyr Consumer Information (Wolters Kluwer)
• Firazyr Consumer Information (Cerner Multum)
• Icatibant Consumer Information (Wolters Kluwer)
• Icatibant Consumer Information (Cerner Multum)